# Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

> **NCT00241410** · PHASE1 · COMPLETED · sponsor: **Allergy Therapeutics** · enrollment: 86 (actual)

## Conditions studied

- Type I Hypersensitivity

## Interventions

- **BIOLOGICAL:** OralvacB2MPL

## Key facts

- **NCT ID:** NCT00241410
- **Lead sponsor:** Allergy Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2010-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00241410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00241410, "Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00241410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*